Brian Levy is the founder of Ocunexus Therapeutics. Ocunexus Therapeutics has raised $59M in total funding. Backed by Domain Associates.
Brian Levy is the CEO of Ocunexus Therapeutics (now known as InflammX Therapeutics), a biopharmaceutical company focused on developing inflammasome inhibition therapeutics for ophthalmologic diseases. He leads the company's efforts with its oral small-molecule agent Xiflam, which is in Phase IIb trials for geographic atrophy and diabetic macular edema.
Full founder directory · Investor directory · Company funding database · Fundraising library